C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression

Withdrawn before enrolling · Phase 2/Phase 3

Conditions studied: Gliomas

In brief

This study will investigate how well Carbon Acetate PET/CT imaging helps to correctly identify recurrent tumor versus post treatment effects (radionecrosis) in patients with previously treated high grade brain gliomas.

Key facts

Study ID

NCT01961934

Run by

Phoenix Molecular Imaging

People needed

0

Starts

2014-05-01

Expected to finish

2018-05-01

Last updated by the study team

2016-09-28

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients age 18-70
• Pathologically confirmed World Health Organization (WHO) grade 3 or 4 glioma
• ECOG/Zubrod 0-2
• Prior external beam radiotherapy to 59.4-60 Gray by 1.8-2 Gy fractions
• Post-radiotherapy contrast-enhanced cranial MRI obtained at least 6 weeks after the completion of external beam radiotherapy shows enhancing anomaly (recurrent/progressive tumor versus pseudo-progression versus radionecrosis)
• Patient completed at least a two week course of palliative steroid therapy for this enhancing anomaly
• No prior designated therapy other than steroids for presumed radionecrosis or recurrent tumor
• Patient with no clinical and/or radiological response to steroid therapy
• Patient eligible for stereotactic brain biopsy
• Patient eligible for focal laser therapy

You may not qualify if…

• Patients under the age of 18 years
• Claustrophobic patients

Where it is running

• Phoenix Molecular Imaging — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.